Posted by Michael Wonder on 13 Jul 2017
ICER releases draft evidence report reviewing olaparib, rucaparib, and niraparib for ovarian cancer
12 July 2017 - Public comment period now open until 9 August; requests to make oral comment during public meeting also being accepted.
The Institute for Clinical and Economic Review has released a draft evidence report assessing the comparative clinical effectiveness and value of three poly ADP-ribose polymerase (PARP) inhibitors for treatment of ovarian cancer: olaparib (Lynparza, AstraZeneca), rucaparib (Rubraca, Clovis Oncology), and niraparib (Zejula, Tesaro).
The report, along with draft voting questions, will be open to public comment for four weeks.
